Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum

Key Points

• Abeona is building a commercial infrastructure for ZEVASKYN, its one-time, patient-specific gene therapy for chronic wounds associated with recessive dystrophic epidermolysis bullosa. The therapy’s 84-hour shelf life and specialized manufacturing require close coordination among patients, surgeons and treatment centers.
• The qualified treatment-center network has grown to seven sites, covering regions containing about 40% of the addressable patient population. Physicians and centers have identified more than 100 potential candidates, although management said completed treatments—not biopsies or manufacturing activity—are the key commercial metric.
• Management said more than 95% of commercially insured lives have ZEVASKYN coverage, while manufacturing turnaround is typically 23–26 days. Abeona expects early demand to come mainly from new patients, with repeat treatment potentially occurring after six months to a year and free-cash-flow positivity requiring more than three patients treated per month.

Abeona Therapeutics NASDAQ: ABEO executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during the Morgan Stanley Global Healthcare Conference. Management emphasized that the launch requires a longer foundation-building period than a conventional drug because of the therapy’s individualized manufacturing process, limited shelf life and specialized treatment-center requirements.

President and Chief Executive Officer Vish Seshadri said the company received its first product approval last year and treated its first commercial patient with ZEVASKYN in December. He described the transition from a development-stage biotechnology company to a commercial organization as a cultural shift, with Abeona expanding from roughly 80 to 90 research-and-development employees two to three years ago to about 250 employees supporting manufacturing and supply operations.

Therapy targets chronic wounds in RDEB

Seshadri described RDEB as a genetic connective-tissue disorder in which patients lack a functional gene for collagen VII, a protein that helps hold skin layers together. The resulting loss of skin integrity can lead to chronic wounds, blistering, infections, sepsis and other complications, he said. Patients may require wound-dressing changes several times weekly, with each session lasting six to seven hours, according to Seshadri.

Historically, patients have relied primarily on antibiotics and bandage changes, he said. More recently, genetic medicines have entered the treatment landscape, including topical therapies designed to supply the relevant gene on a temporary basis.

ZEVASKYN uses a patient’s own cells, which are modified to produce collagen VII and applied as sheets to wounds in a one-time treatment for a given wound. Seshadri said Abeona has clinical data extending as far as 12 years from a single application, including data presented at the Society for Investigative Dermatology conference.

In discussing another therapy in the market, Krystal Biotech’s VYJUVEK, Seshadri said the products are intended to serve different needs rather than compete as mutually exclusive treatments. He characterized VYJUVEK as a weekly treatment and said ZEVASKYN may be particularly suited for patients with large, contiguous chronic wound areas. Each ZEVASKYN sheet covers approximately 40 square centimeters, and a batch can contain up to 12 sheets, he said.

Seshadri added that commercially treated ZEVASKYN patients have largely previously received VYJUVEK, underscoring what he described as remaining unmet need among RDEB patients.

Expanding qualified treatment-center network

A central part of the commercial rollout is building a network of qualified treatment centers, or QTCs, capable of coordinating surgeons, anesthesiologists, EB physicians and cell-and-gene-therapy specialists. ZEVASKYN has an 84-hour shelf life, requiring treatment teams to align schedules before Abeona initiates manufacturing for an individual patient.

“It is almost like a solar eclipse needs to be aligned before we can take a manufacturing slot,” Seshadri said.

Chief Commercial Officer Madhav Vasanthavada said the company had aimed to onboard seven centers during the year and has additional sites coming online. He highlighted the University of Florida as a newly added center serving patients in Florida and the broader Southeastern U.S. region.

Management said the current footprint of seven centers covers states where about 40% of the addressable patient population resides. Vasanthavada said the company’s immediate focus is helping activated sites move from their first treatment to treating more patients, while sharing institutional lessons across the network.

• Stanford and Lurie Children’s in Chicago accounted for the bulk of early treated patients, according to Vasanthavada.
• Texas had biopsied a patient during the second quarter, while Children’s Hospital of Philadelphia had biopsied and treated a patient, he said.
• Abeona said physicians and qualified centers have identified more than 100 patients they believe could be candidates for ZEVASKYN.

Vasanthavada said the definitive commercial indicator remains patients receiving treatment, since Abeona recognizes revenue at treatment. The company has stopped providing figures on planned biopsies or products in manufacturing because some factors affecting treatment timing are outside its control.

Access, repeat treatment and manufacturing

On reimbursement, Vasanthavada said more than 95% of commercial insurance lives have coverage for ZEVASKYN, while the company has baseline Medicaid coverage across states. He said a little more than half of patients are commercially insured, with Medicaid patients also representing a significant group and Medicare patients making up about 10%.

According to Vasanthavada, patients and caregivers generally face limited copay or financial obligations, while treatment centers must navigate authorization, payer contracting and payment-rate arrangements. Abeona also offers travel and copay-support programs through Abeona Assist.

Management expects initial utilization to be driven primarily by new patients. Based on clinical-trial experience and physician discussions, Vasanthavada said repeat treatment could occur no sooner than roughly six months to one year after an initial procedure. The company anticipates approximately two treatments per patient over a patient’s lifetime, given the wound area that can be covered in a treatment episode.

On manufacturing, Seshadri said commercial turnaround times have generally ranged from 23 to 26 days, with a standard deviation of less than two days. He said Abeona’s average output has been nine sheets per lot, including outlier lots that produced three sheets, and that the company is working to improve output through continued process optimization.

Looking ahead, Seshadri said investors should watch for expansion of the QTC network, more centers completing treatments and sharing outcomes with peers, and eventual quarter-to-quarter treatment growth. He said the company expects to reach free-cash-flow positivity at more than three patients treated per month, though he said the timing of that milestone is difficult to predict.

About Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing cell and gene therapies for patients with serious and life-threatening genetic diseases. The company's programs are designed to address conditions for which existing treatment options are limited or inadequate.

Abeona's lead product, ZEVASKYN (prademagene zamikeracel, formerly EB-101), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and chronic wounds.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.